T
Terry J. Hamblin
Researcher at University of Southampton
Publications - 190
Citations - 19088
Terry J. Hamblin is an academic researcher from University of Southampton. The author has contributed to research in topics: Chronic lymphocytic leukemia & Antibody. The author has an hindex of 54, co-authored 190 publications receiving 18592 citations. Previous affiliations of Terry J. Hamblin include Royal Bournemouth Hospital & Laboratory of Molecular Biology.
Papers
More filters
Journal ArticleDOI
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
Peter L. Greenberg,Christopher Cox,Michelle M. LeBeau,Pierre Fenaux,Pierre Morel,Guillermo Sanz,Miguel A. Sanz,Teresa Vallespi,Terry J. Hamblin,David Oscier,Kazuma Ohyashiki,Keisuke Toyama,Carlo Aul,Ghulam J. Mufti,John M. Bennett +14 more
TL;DR: The International MDS Risk Analysis Workshop combined cytogenetic, morphological, and clinical data from seven large previously reported risk-based studies that had generated prognostic systems as discussed by the authors.
Journal ArticleDOI
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
Terry J. Hamblin,Zadie Davis,Zadie Davis,Anne Gardiner,Anne Gardiner,David G. Oscier,David G. Oscier,Freda K. Stevenson,Freda K. Stevenson +8 more
TL;DR: In this paper, the authors sequenced the Ig V(H) genes of the tumor cells of 84 patients with CLL and correlated their findings with clinical features, finding that the lack of somatic mutation and trisomy 12 was associated with a less favorable prognosis.
Journal ArticleDOI
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile
Adrian Wiestner,Andreas Rosenwald,Todd S. Barry,George E. Wright,R. Eric Davis,Sarah E. Henrickson,Hong Zhao,Rachel E. Ibbotson,Jenny A. Orchard,Zadie Davis,Maryalice Stetler-Stevenson,Mark Raffeld,Diane C. Arthur,Gerald E. Marti,Wyndham H. Wilson,Terry J. Hamblin,David Oscier,Louis M. Staudt +17 more
TL;DR: ZAP-70 expression and IgVH mutation status were comparable in their ability to predict time to treatment requirement following diagnosis, and reverse transcriptase-polymerase chain reaction and immunohistochemical assays for ZAP- 70 expression can be applied clinically and would yield important prognostic information for patients with CLL.
Journal ArticleDOI
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
Daniel Catovsky,Susan M. Richards,Estella Matutes,David Oscier,Mjs Dyer,RF Bezares,Andrew R. Pettitt,Terry J. Hamblin,Donald Milligan,J.A. Child,Hamilton,Claire Dearden,Alastair G. Smith,Andrew G. Bosanquet,Zadie Davis,Vasantha Brito-Babapulle,Monica Else,Rachel Wade,Peter Hillmen +18 more
TL;DR: A meta-analysis of these data and those of two published phase III trials showed a consistent benefit for the fludarabine plus cyclophosphamide regimen in terms of progression-free survival.
Journal ArticleDOI
CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.
Terry J. Hamblin,Jenny A. Orchard,Rachel E. Ibbotson,Zadie Davis,Peter Thomas,Freda K. Stevenson,David Oscier +6 more
TL;DR: CD38 expression is an independent risk factor that can be used with IgV(H) mutations and clinical stage to select patients with B-CLL with the worst prognoses.